TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$18.74
-0.04 (-0.19%)
▼
5d:
+3.74%
30d:
+2.83%
90d:
+20.17%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TAK is fairly valued with market pricing in 4.9% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: TAK is fairly valued with market pricing in 4.9% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
18.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $18.73, which is considered extended relative to its 30-day fair value range of $17.91 to $18.56. The stock's valuation (Forward PE: 0.2) is in line with its historical norms (0.2). At these levels, the market is pricing in 4.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is approaching resistance at $18.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is approaching resistance at $18.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$17.91 -
$18.56
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($19.73)
- NEUTRAL: Market pricing in 4.9% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$17.91 -
$18.56
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$17.78
Resistance Level
$18.90
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.20
Wall Street Target
$19.73
(+5.1%)
Revenue Growth (YoY)
4.2%
Earnings Growth (YoY)
330.2%
Profit Margin
2.5%
Valuation Premium vs History
+4.9% premium
PE vs Historical
0.2 vs 0.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.9%
(market-implied from PE analysis)
1-Year Target
$19.69
(+5%)
2-Year Target
$20.65
(+10%)
3-Year Target
$21.67
(+15%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$21.93
(+17%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 93.0%)
$7164.61
(+38071%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$63.35
(+238%)
Bear:
(PE: 0.2, Growth: 93.0%)
$53.85
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (0x PE) as earnings recover.
Forward PE: 12.48 | Forward EPS (Implied): $1.43
Bull Case
$21.57
(+21%)
Analyst growth 15.0%, PE expands to 13.1
Base Case
$17.86
(0%)
Market implied 0.0%, PE stable at 12.5
Bear Case
$13.66
(-24%)
Severe decline -15.0%, PE contracts to 11.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 02, 2026 12:10 PM ET
Data refreshes hourly during market hours. Next update: 1:10 PM
Data refreshes hourly during market hours. Next update: 1:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$38 | 64 BUY |
